Skip to main content
MSF logo
  • Media room
  • Contact
  • msf.org
  • About us
    • About the Access Campaign
      • Our 2020 wishlist 🌟
    • Media room
    • Latest news
    • Jobs
    Wishlist 2020

    🌟Read and share our wishes

    Get Involved!

    Sign up to stay updated and find out how you can get involved.

    I want to receive emails from MSF and I have read and agree with the privacy policy.

  • Our work
    • COVID-19 Actions for access 💊💉🔬
      • Explainer: A bold proposal at the WTO by India and South Africa
      • Spotlight on: COVID-19 vaccines
    • Diabetes
    • Drug-resistant infections
    • HIV/AIDS
    • Hepatitis C
    • Patents and intellectual property
      • The Patent Oppositions Database
      • Spotlight on: Access to medicines in Europe
      • Spotlight on: TRIPS, TRIPS Plus
    • Research and development
      • Spotlight on: the Big Pharma double-dip
    • Tropical and neglected diseases
      • Spotlight on: Snakebite
    • Tuberculosis
    • Vaccines
    Wishlist 2020

    🌟Read and share our wishes

    Get Involved!

    Sign up to stay updated and find out how you can get involved.

    I want to receive emails from MSF and I have read and agree with the privacy policy.

  • Get involved
    • Active campaigns
      • COVID-19 Actions for access 💊💉🔬
      • 20 years of Advocacy in Action
    • Campaign success stories
      • #NoMoreTears Johnson & Johnson Can you hear us?
      • Novartis 'Drop the case'
      • Trans-pacific Partnership (TPP)
    MSF Access Missions Medicines Should Not be a Luxury
    Take Action

    Get Involved!

    Sign up to stay updated and find out how you can get involved.

    I want to receive emails from MSF and I have read and agree with the privacy policy.

  • Resources
    • ⚠️ COVID-19
    • Events
    • Feature stories
    • Infographics
    • Interviews
    • Letters
    • Opinion articles
    • Photo stories
    • Press releases
    • Publications
      • Fact sheets
      • Issue briefs
      • Reports
      • Report series
      • Technical briefs
      • All types
    • Research articles
    • Statements
    • Topic overview pages
    • Spotlight pages
    • Videos
    Wishlist 2020

    🌟Read and share our wishes

    Get Involved!

    Sign up to stay updated and find out how you can get involved.

    I want to receive emails from MSF and I have read and agree with the privacy policy.

  • Media room
  • Contact
  • msf.org
  • About us
    • About the Access Campaign
      • Our 2020 wishlist 🌟
    • Media room
    • Latest news
    • Jobs
    Wishlist 2020

    🌟Read and share our wishes

    Get Involved!

    Sign up to stay updated and find out how you can get involved.

    I want to receive emails from MSF and I have read and agree with the privacy policy.

  • Our work
    • COVID-19 Actions for access 💊💉🔬
      • Explainer: A bold proposal at the WTO by India and South Africa
      • Spotlight on: COVID-19 vaccines
    • Diabetes
    • Drug-resistant infections
    • HIV/AIDS
    • Hepatitis C
    • Patents and intellectual property
      • The Patent Oppositions Database
      • Spotlight on: Access to medicines in Europe
      • Spotlight on: TRIPS, TRIPS Plus
    • Research and development
      • Spotlight on: the Big Pharma double-dip
    • Tropical and neglected diseases
      • Spotlight on: Snakebite
    • Tuberculosis
    • Vaccines
    Wishlist 2020

    🌟Read and share our wishes

    Get Involved!

    Sign up to stay updated and find out how you can get involved.

    I want to receive emails from MSF and I have read and agree with the privacy policy.

  • Get involved
    • Active campaigns
      • COVID-19 Actions for access 💊💉🔬
      • 20 years of Advocacy in Action
    • Campaign success stories
      • #NoMoreTears Johnson & Johnson Can you hear us?
      • Novartis 'Drop the case'
      • Trans-pacific Partnership (TPP)
    MSF Access Missions Medicines Should Not be a Luxury
    Take Action

    Get Involved!

    Sign up to stay updated and find out how you can get involved.

    I want to receive emails from MSF and I have read and agree with the privacy policy.

  • Resources
    • ⚠️ COVID-19
    • Events
    • Feature stories
    • Infographics
    • Interviews
    • Letters
    • Opinion articles
    • Photo stories
    • Press releases
    • Publications
      • Fact sheets
      • Issue briefs
      • Reports
      • Report series
      • Technical briefs
      • All types
    • Research articles
    • Statements
    • Topic overview pages
    • Spotlight pages
    • Videos
    Wishlist 2020

    🌟Read and share our wishes

    Get Involved!

    Sign up to stay updated and find out how you can get involved.

    I want to receive emails from MSF and I have read and agree with the privacy policy.

Medicines shouldn’t be a luxury

Take action!
Get involved
MSF Actions On Covid-19 Pandemic

Covid-19: An overview

No patents or profiteering on drugs, tests, and vaccines in pandemic

Get involved!
Shailly Gupta

Price announced by @TBAlliance for a six-month treatment course for #tuberculosis drug pretomanid at US$364 is still too high: says @SharonannMSF @MSF_access at 50th @UnionConference in Hyderabad msfaccess.org/price-announce…

00:53 - 29 Oct 2019

Navigate

  • About the Access Campaign
  • 1999-2019: 20 Years of Advocacy in Action
  • Contact us
  • Get involved
  • Our work
  • Resources
  • Search

Get updates

  • Sign up for our newsletter
  • Privacy & data protection information

Contact

MSF Access Campaign
Médecins Sans Frontières
Rue de Lausanne 78
P.O Box 1016
CH-1211 Geneva 1, Switzerland
Phone:+41 22 849 8484 Fax:+41 22 849 8404
E-mail: access(at)msf.org

Follow us on Twitter and Facebook

  • Facebook
  • Twitter
  • Vimeo
Medicines Shouldn't Be A Luxury